1. Home
  2. BHST vs IMUX Comparison

BHST vs IMUX Comparison

Compare BHST & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioHarvest Sciences Inc.

BHST

BioHarvest Sciences Inc.

HOLD

Current Price

$5.30

Market Cap

137.1M

Sector

N/A

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$0.62

Market Cap

85.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHST
IMUX
Founded
2007
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
137.1M
85.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BHST
IMUX
Price
$5.30
$0.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$13.00
$6.00
AVG Volume (30 Days)
74.2K
1.2M
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$32,720,000.00
N/A
Revenue This Year
$116.40
N/A
Revenue Next Year
$55.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
45.88
N/A
52 Week Low
$4.72
$0.56
52 Week High
$12.80
$1.39

Technical Indicators

Market Signals
Indicator
BHST
IMUX
Relative Strength Index (RSI) 31.60 36.87
Support Level $6.12 $0.66
Resistance Level $6.03 $0.70
Average True Range (ATR) 0.52 0.04
MACD 0.02 -0.00
Stochastic Oscillator 5.88 1.40

Price Performance

Historical Comparison
BHST
IMUX

About BHST BioHarvest Sciences Inc.

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: